AstraZeneca: Reimagining Pharmaceutical Procurement
In the rigorous world of pharmaceutical procurement, the definition of value is changing. Where finance and spend traditionally equalled cost-control and supply security, procurement teams today are judged on how a supplier decision affects patient outcomes, system resilience and a product’s environmental footprint.
Leading that shift is AstraZeneca’s Ambition Zero Carbon programme. Launched in 2020, the strategy reframes category management: teams no longer buy components in isolation but manage product categories, from active pharmaceutical ingredients to packaging and logistics, through the lens of carbon intensity and supplier transition plans.
Strategic playbooks for decarbonisation
That reframing is practical as well as rhetorical. The company reports that the vast majority of its emissions are tied up in Scope 3 sources, AstraZeneca’s disclosure ranges around the mid-90s percentage depending on the reporting year, so reducing upstream emissions is the decisive lever for meeting corporate net-zero commitments. For procurement, that means shifting from broad mandates to targeted category playbooks that prioritise high-emission inputs such as raw materials, energy-intensive suppliers and transport.
Category decarbonisation is being run like any other strategic commercial programme: segment the supplier base, rank by emissions and spend, then deploy tailored interventions. AstraZeneca’s engagement playbook aims to reach roughly 3,500 suppliers, representing ~95% of spend, with science-based targets and supplier support by 2025. That is a procurement-led growth strategy: fewer carbon-intensive suppliers and more resilient, transparent supply chains make the product offering more attractive to risk-conscious buyers such as public health systems.
Building supplier capacity
Procurement’s role moves toward capacity building. AstraZeneca requires suppliers to align to SBTi pathways and uses coordinated programmes – including CDP Supply Chain engagement and shared platforms like Energize – to help smaller vendors access renewables and measure progress. This isn't merely about ticking boxes for compliance, it's a strategic co-investment in supplier capabilities that effectively raises the standard for the entire category The company has publicly committed investment to support the transition, signalling that sustainability is mission-critical rather than optional.
That supplier focus is already measurable. AstraZeneca reports strong progress on sustainable packaging and fleet electrification, and its supplier disclosure efforts have rapidly scaled. Procurement teams now track emissions intensity alongside traditional total cost of ownership metrics, treating lower carbon intensity as a product differentiator for hospital and health-system purchasers.
The leadership case for resilience
The leadership case helps land the change internally. “The momentum across our company is continuing in 2026…” Chief Executive, Pascal Soriot, recently told investors, underlining how sustainability and pipeline performance are being presented as complementary drivers of long-term resilience. At the supplier level, Jenny Perrie, AstraZeneca’s Scope 3 lead in Global Procurement, sums up the procurement imperative: “Our Scope 3 footprint is more than 20 times greater than our Scope 1 and 2 footprint and our ambitions will only be achieved through close collaboration with our supply chain partners.”
For procurement leaders in pharma, AstraZeneca offers a practical blueprint: treat category management as decarbonisation infrastructure, make supplier transition measurable and invest in supplier capability. The result is not just a cleaner balance sheet, it’s a stronger product proposition for customers whose own sustainability obligations increasingly shape purchasing decisions.
